Crinetics Pharmaceuticals, Inc. announced significant findings from its recent research on the investigational candidate paltusotine for the treatment of acromegaly. The studies, presented at the American Association of Clinical Endocrinology Annual Meeting 2025, highlighted paltusotine's rapid and durable effects in managing IGF-1 levels in surgically naïve patients, indicating it was well tolerated. Additionally, the research underscored the considerable symptom burden that patients on long-acting injectable somatostatin analogs may experience. These developments suggest that, if approved, paltusotine, a novel once-daily oral medication, could represent a meaningful advancement in the standard of care for individuals with acromegaly. Regulatory reviews in the U.S. and EU are progressing, with a PDUFA action date set for September 25 in the U.S.